Key result
IVIG cuts Kawasaki coronary artery lesions ~84%, reducing prevalence from 25% to 4%.
Why the study?
There are ongoing efforts to determine the underlying causes of Kawasaki disease, with prodromal viral illness suspected to trigger adverse immune-mediated responses in genetically predisposed children.
Kawasaki disease (KD) remains the most common cause of pediatric acquired heart disease in high-resource countries.1 When left untreated, 25% of children with KD will develop coronary artery aneurysms. However, if treated in a timely manner with intravenous immunoglobulin (IVIG), the prevalence of coronary artery lesions decreases to about 4%.1 Since its initial description, there have been significant ongoing efforts to determine the underlying causes of KD. A leading suspected risk factor, among others, has remained a prodromal viral illness that is thought to trigger KD through adverse immune-mediated responses in genetically predisposed children.
No takes yet. Share an insight, caveat, or question.
Oliver et al. (2025) conducted an editorial in Kawasaki disease. COVID-19 Pandemic was evaluated. Intravenous immunoglobulin (IVIG) treatment for Kawasaki disease decreases the prevalence of coronary artery lesions from 25% in untreated children to about 4%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: